Results 31 to 40 of about 19,009 (196)

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity [PDF]

open access: yes, 2019
Background: Acute myeloid leukemia mainly affects adult patients. Complete remission for patients younger than 60 years, who are candidates for standard induction therapy, is achieved in 60%–80% of cases.
E. Roger   +17 more
core   +1 more source

Pre-clinical evaluation of the hypomethylating agent decitabine for the treatment of T-cell lymphoblastic lymphoma [PDF]

open access: yes, 2023
T-cell lymphoblastic lymphoma (T-LBL) is a rare and aggressive lymphatic cancer, often diagnosed at a young age. Patients are treated with intensive chemotherapy, potentially followed by a hematopoietic stem cell transplantation.
Putteman, TomGE328020034189810000-0001-5098-431761cf357c-7464-11ea-8d7b-958563a620f4   +21 more
core   +3 more sources

Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation

open access: yesMedComm, 2023
Patients with relapsed/refractory classical Hodgkin lymphoma (cHL) achieve complete response (CR) after decitabine‐plus‐camrelizumab therapy, while long‐term outcome especially after treatment discontinuation remains unclear.
Chunmeng Wang   +10 more
doaj   +1 more source

Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma. [PDF]

open access: yesPLoS ONE, 2014
Cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) reduces survival. In this study we hypothesized that methylation of key genes mediates cisplatin resistance.
Chi T Viet   +5 more
doaj   +1 more source

Low-dose decitabine increases peripheral natural killer T (NKT)-like cell proportions in patients with chronic myeloid neoplasms

open access: yesCancer Pathogenesis and Therapy
Decitabine is widely used in the treatment of chronic myeloid neoplasms, potentially through its immunomodulatory effects on CD8+ T cells and natural killer (NK) cells.
Zhanqiang Zhang   +8 more
doaj   +1 more source

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia

open access: yesTherapeutic Advances in Hematology, 2023
Decitabine, a member of the 5-azanucleosides, has a dose-dependent mechanism of action in vitro : termination of DNA replication at high doses, and inhibition of DNA methyltransferase at low doses.
Robert Briski   +3 more
doaj   +1 more source

Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia

open access: yesHaematologica, 2014
Hypomethylating agents are widely used in patients with myelodysplastic syndromes and unfit patients with acute myeloid leukemia. However, it is not well understood why only some patients respond to hypomethylating agents.
Haiyang Yun   +13 more
doaj   +1 more source

Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan

open access: yesnpj Breast Cancer, 2023
TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 expression.
Ming Zhao   +12 more
doaj   +1 more source

Decitabine encapsulation in nanovector to improve acute myeloid leukemia treatment [PDF]

open access: yes, 2018
Acute myeloid leukemia (AML) mainly affects adult patients, and for older ones unfit for intensive chemotherapy only few therapies are available. Hypomethylating agents, as decitabine, is a labeled option but its plasma half-life is short whereas a long ...
E. Roger   +5 more
core   +2 more sources

Loss of E3 Ubiquitin Ligase RINES via CpG Methylation Relieves Suppression of STAT3 and MYC, Facilitating Multiple Tumorigeneses

open access: yesAdvanced Science, EarlyView.
Dysregulated protein modifications drive tumorigenesis. RINES, an E3 ubiquitin ligase, represses tumor cell proliferation and metastasis by facilitating RING domain‐dependent, ubiquitin–proteasome‐mediated degradation of STAT3 and MYC, which consequently restrains cancer stemness and oncogenic progression.
Lili Li   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy